CT-guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy
Autor: | Jin Na Li, Su Qing Tian, Junjie Wang, Hui Shu Yuan, Rui Jie Yang, Yu Liang Jiang |
---|---|
Rok vydání: | 2009 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Radioactive seed medicine.medical_treatment Brachytherapy Iodine Radioisotopes Internal medicine medicine Humans Aged Chemotherapy Recurrent Rectal Carcinoma Hematology business.industry Rectal Neoplasms General Medicine Seed Implantation Middle Aged Surgery Radiation therapy Treatment Outcome Oncology Multiple therapy Female Neoplasm Recurrence Local business Tomography X-Ray Computed Follow-Up Studies |
Zdroj: | Medical oncology (Northwood, London, England). 27(2) |
ISSN: | 1559-131X |
Popis: | The recurrent carcinoma has been difficult to manage after surgery and radiotherapy, extensive resection of locally recurrent rectal cancer is associated with significant morbidity and mortality. Re-irradiation, even in combination with chemotherapy has shown very short survival. We assess the feasibility and efficacy of CT-guided interstitial permanent brachytherapy with (125)I or (103)Pd seeds for recurrent rectal cancer after multiple treatments. Fifteen patients with locally recurrent rectal carcinoma received (125)I or (103)Pd seed implants under CT guidance. The minimal peripheral dose of seed implants was 110-165 Gy (median 150 Gy). Two weeks after seed implantation, a 50 Gy of stereotactic radiotherapy was given to one patient; four patients received 2-4 cycles of chemotherapy. A median follow-up was 8 months (range 4-50 months). The duration of pain-free survival was 0-50 months (median 7 months). Local control was maintained for 3-50 months (median 7 months). The 1- and 2-year local controls were 16.2 and 8.1%, respectively. Eleven patients died: two (18.2%) of local recurrence, seven (63.6%) of local recurrence and metastases, and two (18.2%) of metastases. Four patients (26.7%) survived the median survival was 9 months. The 1- and 2-year actuarial overall survival rates were 42.9% and 10.7%, respectively. One patient (7.6%) experienced a grade 4 toxic event; there was no associated neuropathy. CT-guided radioactive seed implantation is feasible and safe as a salvage or palliative pain relief treatment for patients with recurrent rectal cancers after surgery and radiotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |